Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin
- 29 July 2008
- journal article
- Published by Wiley in Transfusion
- Vol. 48 (8), 1739-1753
- https://doi.org/10.1111/j.1537-2995.2008.01717.x
Abstract
BACKGROUND: Plasma fractionators have implemented many improvements over the past decade directed toward reducing the likelihood of pathogen transmission by purified blood products, yet little has been published attempting to assess the overall impact of these improvements on the probability of safety of the final product.Keywords
This publication has 91 references indexed in Scilit:
- Neutralization of human parvovirus B19 by plasma and intravenous immunoglobulinsTransfusion, 2007
- A probabilistic model for analyzing viral risks of plasma‐derived medicinal productsTransfusion, 2007
- Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infectionAIDS, 2007
- Quantification of hepatitis B virus genomes and infectivity in human serum samplesTransfusion, 2006
- Viral safety of Nanogam®, a new 15 nm‐filtered liquid immunoglobulin productVox Sanguinis, 2005
- Parvovirus B19 transmission by a high‐purity factor VIII concentrateTransfusion, 2005
- Antihuman Factor V Antibodies After Use of Relatively Pure Bovine ThrombinThe Annals of Thoracic Surgery, 2005
- Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patientThe Lancet, 2004
- Exposure of Mice to Topical Bovine Thrombin Induces Systemic AutoimmunityThe American Journal of Pathology, 2001
- Ultrapure plasma factor VIII produced by anti-FVIIIc immunoaffinity chromatography and solvent/detergent viral inactivation. Characterization of the Method M process and Hemofil M antihemophilic factor (human)Annals of Hematology, 1991